CAT-BLAST: Engineered bacteria for robust targeting and elimination of cancer-associated fibroblasts

References

[1] Mao, Xiaoqi, Jin Xu, Wei Wang, Chen Liang, Jie Hua, Jiang Liu, Bo Zhang, et al. 2021. “Crosstalk Between Cancer-Associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives.” Molecular Cancer 20: 131. https://doi.org/10.1186/s12943-021-01428-1

[2] Jia, Hongyuan, Xingmin Chen, Linling Zhang, and Meihua Chen. 2025. “Cancer Associated Fibroblasts in Cancer Development and Therapy.” Journal of Hematology & Oncology 18: 36. https://doi.org/10.1186/s13045-025-01688-0

[3] Su, Shicheng, Jianing Chen, Herui Yao, Jiang Liu, Shubin Yu, Liyan Lao, Minghui Wang, et al. 2018. “CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness.” Cell 172: 841–56.e16. https://doi.org/10.1016/j.cell.2018.01.009

[4] Chen, Xueman, and Erwei Song. 2019. “Turning Foes to Friends: Targeting Cancer-Associated Fibroblasts.” Nature Reviews Drug Discovery 18: 99–115. https://doi.org/10.1038/s41573-018-0004-1

[5] Yang, Dakai, Jing Liu, Hui Qian, and Qin Zhuang. 2023. “Cancer-Associated Fibroblasts: From Basic Science to Anticancer Therapy.” Experimental & Molecular Medicine 55: 1322–32. https://doi.org/10.1038/s12276-023-01013-0

[6] Busek, Petr, Rosana Mateu, Michal Zubal, Lenka Kotackova, Aleksi Sedo. 2018. “Targeting Fibroblast Activation Protein in Cancer - Prospects and Caveats.” Frontiers in Bioscience-Landmark 23: 1933–68. https://doi.org/10.2741/4682

[7] Shahvali, Sedigheh, Niloufar Rahiman, Mahmoud Reza Jaafari, and Leila Arabi. 2023. “Targeting Fibroblast Activation Protein (FAP): Advances in CAR-T Cell, Antibody, and Vaccine in Cancer Immunotherapy.” Drug Delivery and Translational Research 13: 2041–56. https://doi.org/10.1007/s13346-023-01308-9

[8] Scott, Andrew M., Greg Wiseman, Sydney Welt, Alex Adjei, Fook-Thean Lee, Wendie Hopkins, Chaitan R. Divgi, et al. 2003. “A Phase I Dose-Escalation Study of Sibrotuzumab in Patients With Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer.” Clinical Cancer Research 9: 1639–47. https://www.ncbi.nlm.nih.gov/pubmed/12738716

[9] Hofheinz, Ralf, S. E. al-Batran, F. Hartmann, G. Hartung, D. Jager, C. Renner, P. Tanswell, et al. 2003. “Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients With Metastatic Colorectal Cancer.” Onkologie 26: 44–8. https://doi.org/10.1159/000069863

[10] Kakarla, Sunitha, Kevin K. H. Chow, Melinda Mata, Donald R. Shaffer, Xiao-Tong Song, Meng-Fen Wu, Hao Liu, et al. 2013. “Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma.” Molecular Therapy 21: 1611–20. https://doi.org/10.1038/mt.2013.110

[11] Tran, Eric, Dhanalakshmi Chinnasamy, Zhiya Yu, Richard A. Morgan, Chyi-Chia Richard Lee, Nicholas P. Restifo, and Steven A. Rosenberg. 2013. “Immune Targeting of Fibroblast Activation Protein Triggers Recognition of Multipotent Bone Marrow Stromal Cells and Cachexia.” Journal of Experimental Medicine 210: 1125–35. https://doi.org/10.1084/jem.20130110

[12] Nguyen, Dinh-Huy, Ari Chong, Yeongjin Hong, and Jung-Joon Min. 2023. “Bioengineering of Bacteria for Cancer Immunotherapy.” Nature Communications 14: 3553. https://doi.org/10.1038/s41467-023-39224-8

[13] Vincent, Rosa L., Candice R. Gurbatri, Fangda Li, Ana Vardoshvili, Courtney Coker, Jongwon Im, Edward R. Ballister, et al. 2023. “Probiotic-Guided CAR-T Cells for Solid Tumor Targeting.” Science 382: 211–8. https://doi.org/10.1126/science.add7034

[14] Huang, Xuehui, Jingmei Pan, Funeng Xu, Binfen Shao, Yi Wang, Xing Guo, and Shaobing Zhou. 2021. “Bacteria-Based Cancer Immunotherapy.” Advanced Science 8: 2003572. https://doi.org/10.1002/advs.202003572

[15] Gurbatri, Candice R., Nicholas Arpaia, and Tal Danino. 2022. “Engineering Bacteria as Interactive Cancer Therapies.” Science 378: 858–64. https://doi.org/10.1126/science.add9667

[16] Zhou, Yuxi, and Yong Han. 2022. “Engineered Bacteria as Drug Delivery Vehicles: Principles and Prospects.” Engineering Microbiology 2: 100034. https://doi.org/10.1016/j.engmic.2022.100034

[17] Kley, Nikolai, Jan Tavernier, and Anje Cauwels. 2021. “Fibroblast Binding Agents and Use Thereof.” United States Orionis Biosciences Universiteit Gent 20210023167. https://patents.google.com/patent/US10988538B2/pt

[18] Piñero-Lambea, Carlos, Gustavo Bodelón, Rodrigo Fernández-Periáñez, Angel M. Cuesta, Luis Álvarez-Vallina, and Luis Ángel Fernández. 2015. “Programming Controlled Adhesion of E. Coli to Target Surfaces, Cells, and Tumors With Synthetic Adhesins.” ACS Synthetic Biology 4: 463–73. https://doi.org/10.1021/sb500252a

[19] Murase, Kazunori. 2022. “Cytolysin A (ClyA): A Bacterial Virulence Factor with Potential Applications in Nanopore Technology, Vaccine Development, and Tumor Therapy.” Toxins 14: 78. https://doi.org/10.3390/toxins14020078

[20] Sathyanarayana, Pradeep, Sandhya S. Visweswariah, K. Ganapathy Ayappa. 2021. “Mechanistic Insights into Pore Formation by an α-Pore Forming Toxin: Protein and Lipid Bilayer Interactions of Cytolysin A.” Accounts of Chemical Research 54: 120–31. https://doi.org/10.1021/acs.accounts.0c00551

RIGHTS & PERMISSIONS

2026 The Author(s). iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.